The use of hepatocytes in evaluating time-dependent inactivation of P450 in vivo

Bibliography

• Guidance for Industry. Drug Interaction Studies – Study Design, Data Analysis, and Implications for Dosing and Labeling. Available at: URL: www.fda.gov/cder/guidance/6695dft.pdf [Accessed January 2008]
   Google Scholar
• Brown HS, Griffin M, Houston JB. Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metab Dispos 2007;35:293-301
   PubMed Web of Science ®Google Scholar
• Brown HS, Chadwick A, Houston JB. Use of isolated hepatocyte reparations for P450 inhibition studies: comparison with microsomes for Ki determination. Drug Metab Dispos 2007;35:2119-26
   PubMed Web of Science ®Google Scholar
• Di Marco A, Yao D, Laufer R. Demethylation of radiolabelled dextromethorphan in rat microsomes and intact hepatocytes. Eur J Biochem 2003;270:3768-77
   PubMedGoogle Scholar
• Engtrakul JJ, Foti RS, Strelevitz TJ, Fisher MB. Altered AZT (3′-azido-3′-deoxythymidine) glucuronidation kinetics in liver microsomes as an explanation for underprediction of in vivo clearance: comparison to hepatocytes and effect of incubation environment. Drug Metab Dispos 2005;33:1621-7
   PubMed Web of Science ®Google Scholar
• Hallifax D, Rawden HC, Hakooz N, Houston JB. Prediction of metabolic clearance using cryopreserved human hepatocytes: kinetic characteristics for five benzodiazepines. Drug Metab Dispos 2005;33:1852-8
   PubMed Web of Science ®Google Scholar
• McGinnity DF, Tucker J, Trigg S, Riley RJ. Prediction of CYP2C9-mediated drug-drug interactions: a comparison using data from recombinant enzymes and human hepatocytes. Drug Metab Dispos 2005;33:1700-7
   PubMed Web of Science ®Google Scholar
• Riley RJ, McGinnity DF, Austin RP. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos 2005;33:1304-11
   PubMed Web of Science ®Google Scholar
• McGinnity DF, Berry AJ, Kenny JR, Grime K, Riley RJ. Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes. Drug Metab Dispos 2006;34:1291-300
   PubMed Web of Science ®Google Scholar
• Shou M. Prediction of pharmacokinetics and drug-drug interactions from in vitro metabolism data. Curr Opin Drug Discov Devel 2006;8:66-77
   Web of Science ®Google Scholar
• Venkatakrishnan K, Obach RS. Drug-drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation. Curr Drug Metab 2007;8:449-62
   PubMed Web of Science ®Google Scholar
• Kalgutkar AS, Obach RS, Maurer TS. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. Curr Drug Metab 2007;8:407-47
   PubMed Web of Science ®Google Scholar
• Silverman RB. Mechanism-Based Enzyme Inactivators. Contemporary enzyme kinetics and mechanism. 2nd edition. Academic Press; 1988
   Google Scholar
• Zhang D, Ogan M, Gedamke R, et al. Protein covalent binding of maxipost through a cytochrome P450-mediated ortho-quinone methide intermediate in rats. Drug Metab Dispos 2003;31:837-45
   PubMed Web of Science ®Google Scholar
• Segel IH. Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady State Enzyme Systems. Wiley & Sons, Inc., New York; 1975
   Google Scholar
• Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 1998;50:387-412
   PubMed Web of Science ®Google Scholar
• Kitz R, Wilson IB. Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J Biol Chem 1962;237:3245-9
   PubMed Web of Science ®Google Scholar
• Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A. Kinetic values for mechanism-based enzyme inhibition: assessing the bias introduced by the conventional experimental protocol. Eur J Pharm Sci 2005;26:334-40
   PubMed Web of Science ®Google Scholar
• Ghanbari F, Rowland-Yeo K, Bloomer JC, et al. A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation. Curr Drug Metab 2006;7:315-34
   PubMed Web of Science ®Google Scholar
• Wilkinson GR. Clearance approaches in pharmacology. Pharmacol Rev 1987;39:1-47
   PubMed Web of Science ®Google Scholar
• Rowland M, Tozer TN. Clinical Pharmacokinetics, Concepts and Applications. 3rd edition. Williams and Wilkins; 1996
   Google Scholar
• Zhou S, Yung Chan S, Cher Goh B, et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 2005;44:279-304
   PubMed Web of Science ®Google Scholar
• Mayhew BS, Jones DR, Hall SD. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 2000;28:1031-7
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, Obach RS. In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. Drug Metab Dispos 2005;33:845-52
   PubMed Web of Science ®Google Scholar
• Ito K, Ogihara K, Kanamitsu S, Itoh T. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Dispos 2003;31:945-54
   PubMed Web of Science ®Google Scholar
• Galetin A, Burt H, Gibbons L, Houston JB. Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos 2006;34:166-75
   PubMed Web of Science ®Google Scholar
• Obach RS. Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, impramine, and propranolol. Drug Metab Dispos 2007;25:1359-69
   Google Scholar
• Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998;35:361-90
   PubMed Web of Science ®Google Scholar
• Lim HK, Duczak N Jr, Brougham L, Elliot M, Patel K, Chan K. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes. Drug Metab Dispos 2005;33:1211-9
   PubMed Web of Science ®Google Scholar
• Obach RS, Walsky RL, Venkatakrishnan K. Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 2007;35:246-55
   PubMed Web of Science ®Google Scholar
• Favreau LV, Palamanda JR, Lin CC, Nomeir AA. Improved reliability of the rapid microtiter plate assay using recombinant enzyme in predicting CYP2D6 inhibition in human liver microsomes. Drug Metab Dispos 1999;27:436-9
   PubMed Web of Science ®Google Scholar
• Atkinson A, Kenny JR, Grime K. Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquide chromatography-tandem mass spectrometry analysis. Drug Metab Dispos 2005;33:1637-47
   PubMed Web of Science ®Google Scholar
• Gibbs MA, Kunze KL, Howald WN, Thummel KE. Effect of inhibitor depletion on inhibitory potency: tight binding inhibition of CYP3A by clotrimazole. Drug Metab Dispos 1999;27:596-9
   PubMed Web of Science ®Google Scholar
• Zhao P, Kunze KL, Lee CA. Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes. Drug Metab Dispos 2005;33:853-61
   PubMed Web of Science ®Google Scholar
• Van LM, Hargreaves JA, Lennard MS, Tucker GT, Rostami-Hodjegan A. Inactivation of CYP2D6 by methylenedioxymethamphetamine in different recombinant expression systems. Eur J Pharm Sci 2007;32:8-16
   PubMed Web of Science ®Google Scholar
• Voorman RL, Maio SM, Payne NA, Zhao Z, Koeplinger KA, Wang X. Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A. J Pharmacol Exp Ther 1998;287:381-8
   PubMed Web of Science ®Google Scholar
• Isoherranen N, Kunze KL, Allen KE, Nelson WL, Thummel KE. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 2004;32:1121-31
   PubMed Web of Science ®Google Scholar
• Zhao P, Lee CA, Kunze KL. Sequential metabolism is responsible for diltiazem-induced time-dependent loss of CYP3A. Drug Metab Dispos 2007;35:704-12
   PubMed Web of Science ®Google Scholar
• Templeton IE, Thummel KE, Kharasch ED, et al. Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo. Clin Pharmacol Ther 2008;83:77-85
   PubMed Web of Science ®Google Scholar
• Ernest CS 2nd, Hall SD, Jones DR. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 2005;312:583-91
   PubMed Web of Science ®Google Scholar
• Pichard L, Fabre I, Daujat M, Domergue J, Joyeux H, Maurel P. Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol Pharmacol 1992;41:1047-55
   PubMed Web of Science ®Google Scholar
• Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther 2004;76:178-84
   PubMed Web of Science ®Google Scholar
• Lu P, Shrag ML, Slaughter DE, Raab CE, Shou M, Rodrigues AD. Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos 2003;31:1352-60
   PubMed Web of Science ®Google Scholar
• Roberts BJ, Song BJ, Soh Y, Park SS, Shoaf SE. Ethanol induces CYP2E1 by protein stabilization. Role of ubiquitin conjugation in the rapid degradation of CYP2E1. J Biol Chem 1995;270:29632-5
   PubMed Web of Science ®Google Scholar
• Chien JY, Thummel KE, Slattery JT. Pharmacokinetic consequences of induction of CYP2E1 by ligand stabilization. Drug Metab Dispos 1997;25:1165-75
   PubMed Web of Science ®Google Scholar
• Luo G, Lin J, Fiske WD, et al. Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative. Drug Metab Dispos 2003;31:1170-5
   PubMed Web of Science ®Google Scholar
• Wang YH, Jones DR, Hall SD. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 2004;32:259-66
   PubMed Web of Science ®Google Scholar
• Ito K, Chiba K, Horikawa M, et al. Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? AAPS PharmSci 2002;4:E25
   PubMed Web of Science ®Google Scholar
• Ito K, Brown HS, Houston JB. Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 2004;57:473-86
   PubMed Web of Science ®Google Scholar
• Ito K, Hallifax D, Obach RS, Houston JB. Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab Dispos 2005;33:837-44
   PubMed Web of Science ®Google Scholar
• Kanamitsu S, Ito K, Green CE, Tyson CA, Shimada N, Sugiyama Y. Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharm Res 2000;17:419-26
   PubMed Web of Science ®Google Scholar
• Brown HS, Ito K, Galetin A, Houston JB. Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol 2005;60:508-18
   PubMed Web of Science ®Google Scholar
• Thummel KE, O'Shea D, Paine MF, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996;59:491-502
   PubMed Web of Science ®Google Scholar
• Easterbrook J, Lu C, Sakai Y, Li AP. Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. Drug Metab Dispos 2001;29:141-4
   PubMed Web of Science ®Google Scholar
• Li AP, Lu C, Brent JA, et al. Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem Biol Interact 1999;121:17-35
   PubMed Web of Science ®Google Scholar
• Lu C, Li AP. Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog. Chem Biol Interact 2001;134:271-81
   PubMed Web of Science ®Google Scholar
• Liu X, LeCluyse EL, Brouwer KR, et al. Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration. Am J Physiol 1999;277:G12-21
   PubMed Web of Science ®Google Scholar
• Liu X, Chism JP, LeCluyse EL, Brouwer KR, Brouwer KL. Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. Drug Metab Dispos 1999;27:637-44
   PubMed Web of Science ®Google Scholar
• LeCluyse EL, Alexandre E, Hamilton GA, et al. Isolation and culture of primary human hepatocytes. Methods Mol Biol 2005;290:207-29
   PubMedGoogle Scholar
• Hewitt NJ, Lechón MJ, Houston JB, et al. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 2007;39:159-234
   PubMed Web of Science ®Google Scholar
• Lu C, Miwa GT, Prakash SR, Gan LS, Balani SK. A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome p450 phenotypic data. Drug Metab Dispos 2007;35:79-85
   PubMed Web of Science ®Google Scholar
• McGinnity DF, Collington J, Austin RP, Riley RJ. Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs. Curr Drug Metab 2007;8:463-79
   PubMed Web of Science ®Google Scholar
• Lam JL, Benet LZ. Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. Drug Metab Dispos 2004;32:1311-6
   PubMed Web of Science ®Google Scholar
• Dixit V, Hariparsad N, Li F, Desai P, Thummel KE, Unadkat JD. Cytochrome p450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos 2007;35:1853-9
   PubMed Web of Science ®Google Scholar
• Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A. Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition. Eur J Pharm Sci 2007;31:232-41
   PubMed Web of Science ®Google Scholar
• Roelofsen H, Bakker CT, Schoemaker B, et al. Redistribution of canalicular organic anion transport activity in isolated and cultured rat hepatocytes. Hepatology 1995;21:1649-57
   PubMed Web of Science ®Google Scholar
• Wandel C, Kim RB, Kajiji S, Guengerich P, Wilkinson GR, Wood AJ. P-Glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 1999;59:3944-8
   PubMed Web of Science ®Google Scholar
• Polli JW, Wring SA, Humphreys JE, et al. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 2001;299:620-8
   PubMed Web of Science ®Google Scholar
• Hallifax D, Houston JB. Uptake and intracellular binding of lipophilic amine drugs by isolated rat hepatocytes and implications for prediction of in vivo metabolic clearance. Drug Metab Dispos 2006;34:1829-36
   PubMed Web of Science ®Google Scholar
• Austin RP, Barton P, Mohmed S, Riley RJ. The binding of drugs to hepatocytes and its relationship to physicochemical properties. Drug Metab Dispos 2005;33:419-25
   PubMed Web of Science ®Google Scholar
• Kosuge K, Nishimoto M, Kimura M, Umemura K, Nakashima M, Ohashi K. Enhanced effect of triazolam with diltiazem. Br J Clin Pharmacol 1997;43:367-72
   PubMed Web of Science ®Google Scholar
• Montamat SC, Abernethy DR. N-monodesmethyldiltiazem is the predominant metabolite of diltiazem in the plasma of young and elderly hypertensives. Br J Clin Pharmacol 1987;24:185-9
   PubMed Web of Science ®Google Scholar
• Kanamitsu SI, Ito K, Okuda H, et al. Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-Bromovinyl)uracil. Drug Metab Dispos 2000;28:467-74
   PubMed Web of Science ®Google Scholar
• Komatsu K, Ito K, Nakajima Y, et al. Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments. Drug Metab Dispos 2000;28:475-81
   PubMed Web of Science ®Google Scholar
• Riley RJ, Grime K, Weaver R. Time-dependent CYP inhibition. Expert Opin Drug Metab Toxicol 2007;3:51-66
   PubMed Web of Science ®Google Scholar
• Barton HA, Chiu WA, Woodrow Setzer R, et al. Characterizing uncertainty and variability in physiologically based pharmacokinetic models: state of the science and needs for research and implementation. Toxicol Sci 2007;99:395-402
   PubMed Web of Science ®Google Scholar